Discover everything pharmaceutical scientists need to know about solid form characterisation, starting with API selection.
List view / Grid view
Regs & Legs
Sino Biological announced the formal signing of a lease with Hines and initiation of construction on its new Centre for Bioprocessing (C4B) at its Levit Green facility in Houston, US.
Biovac signs deal with IVI to develop and manufacture oral cholera vaccine (OCV) for African and global markets.
Discover how Malvern Panalytical’s combination of analytical instrumentation and research services can take particle size analysis to the next level.
This Malvern Panalytical guide explores the use of Xray powder diffraction (XRPD) as a powerful tool to develop and improve pharmaceutical formulation.
The College of American Pathologists has given accreditation to Altasciences’ clinical site in Los Angeles, California.
The FDA has cleared the Simcere's investigational new drug application for SIM0237, an anti-PD-L1/IL-15 bi-functional fusion protein, for the treatment of adult patients with advanced solid tumours.
A report has found that increased investment in drug discovery will help the demand for personalised medicine, encouraging the growth of the liquid handling market.
Incannex Healthcare has completed a pre-IND meeting with the FDA for IHL-216A, a drug product for treatment of traumatic brain injury.
Following FDA clearance, Cellenkos will initiate Phase I and Phase Ib trials of CK0803, allogeneic regulatory T cells, in patients with ALS.
Texas Biomed and The Access to Advanced Health Institute have been granted $3.5 million to initiate tuberculosis vaccine research, which includes using genetically diverse animal models.
The Chinese National Medical Products Administration has approved a Phase Ib study of Everest Medicines' EVER001, for potential treatment of glomerular diseases.
Decibel Therapeutics has submitted an IND application for a Phase I/II trial of DB-OTO, a gene therapy candidate to restore hearing.
Silo Pharma says it is preparing a pre-IND package and meeting with the FDA for a topical formulation of ketamine to treat fibromyalgia.
A Boston University researcher has been granted funding for the development pre-clinical models to test potential Nipah virus vaccines.